The European Anatomic Pathology Market is estimated to worth USD 4.74 billion in 2020 and is expected to be growing at a CAGR of 5.77% to reach USD 6.27 billion by 2025.
The market is already pretty huge in this region and is expected to grow even more significantly in the mentioned forecast period. Anatomy Pathology is the branch of medicine that deals with the diagnosis of diseases based on the various levels of examinations of organs and tissues.
Anatomic Pathology features the diagnosis of disease based on the macroscopic, microscopic, biochemical, immunologic, and molecular examination of organs and tissues. The data generated by Anatomy Pathology is further analyzed and is used by doctors for better health management. Anatomy Pathology is one of the branches of the pathology stream, other being the Clinical Pathology.
With most of the countries already being developed, people earn more and can spend more on their health, so the market is pretty big in this region. People have also become prone to more and more harmful diseases as time has changed because of the increasing adaptability of micro-organisms against various medications. This market is facing challenges mainly competing with the Physician Groups, like specialty physicians merging or adding ancillary services and large commercial labs. There is a constant significant reimbursement pressure. These factors may act as growth hurdles for the Anatomy Pathology Market in this region.
This report segmented and sub-segmented into the following categories:
Regional Analysis
Europe is one of the most lucrative markets for the growth of the global anatomic pathology market. Factors such as developed countries and the sound financial strength of people are the reason for this market being so much improved in this region.
Leading companies in the market
This market is extremely disjointed with numerous big and developing players operating in the business. Some of the major companies dominating the market in this region are TPL-Pathology Labs, ARUP Pathology, and Maxdata.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Instruments
5.1.3 Accessories
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 End-User
5.2.1 Introduction
5.2.2 Diagnostics Lab
5.2.3 Hospitals
5.2.4 Physicians' Office Lab
5.2.5 Y-o-Y Growth Analysis, By End-User
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By End-User
5.3 Application
5.3.1 Introduction
5.3.2 Lymphoma
5.3.3 Breast
5.3.4 Lung
5.3.5 Cervical
5.3.6 Colorectal
5.3.7 Prostate
5.3.8 Y-o-Y Growth Analysis, By Application
5.3.9 Market Attractiveness Analysis, By Application
5.3.10 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type End-User
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type End-User
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type End-User
6.1.5.4 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 NeoGenomics Laboratories Inc.
8.3 Laboratory Corporation of America Holdings
8.4 Thermo Fisher Scientific
8.5 Quest Diagnostics Incorporated
8.6 Agilent Technologies
8.7 Danaher Corporation
8.8 Sakura Finetechnical Co. Ltd.
8.9 Metropolis
8.10 IBISWorld’s Pathology Services
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
